A phase 1 clinical study of novel plasma kallikrein inhibitors for the treatment of DME (diabetic macular edema) has been announced by KalVista Pharmaceuticals, a UK based company. The registered study is designed to investigate the safety and tolerability of a plasma kallikrein inhibitor, known as “KVD001”, in subjects with DME. Officially entitled as “An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision”, the trial will be investigating Kalvista’s hypothesis that plasma kallikrein is a critical player in the pathogenesis of diabetic macular edema. The study is been conducted in the US across five centres in California, Indiana, Massachusetts, South Carolina abd Texas.